Soligenix Announces $300,000 NCI SBIR Grant Award Supporting a Phase 2 Trial of orBec® as a Treatment for Chronic GI …

PRINCETON, N.J., Sept. 4, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the National Cancer Institute ...